EMA Authorised: Kigabeq (vigabatrin) — ORPHELIA Pharma

View source ↗

Summary

The EMA has authorised Kigabeq (vigabatrin) by ORPHELIA Pharma for infantile spasms and partial epilepsies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Spasms
• Partial Epilepsy

Drugs mentioned

• Kigabeq (vigabatrin)

Snippet

Status: Authorised. Therapeutic area: Spasms, Infantile;Epilepsies, Partial. MAH: ORPHELIA Pharma. Decision date: 18/02/2026